A Tale of Two Strategies: Institutional Bulls vs. Insider Sales at Axsome

A fascinating divergence is unfolding around Axsome Therapeutics, creating a clear puzzle for market observers. On one side, heavyweight investment firms are building substantial positions, signaling strong conviction. On the other, the company’s own top executives are liquidating millions of dollars worth of their personal holdings. This clash raises a critical question: whose foresight should investors trust?

The institutional money flow tells a story of robust optimism. Recent regulatory filings reveal that Mirae Asset Global Investments significantly increased its stake during the second quarter, boosting its position by 16.5 percent. Concurrently, Ameritas Advisory Services established a brand new position in the biopharmaceutical company. These moves by professional asset managers indicate a firm belief in Axsome’s long-term growth trajectory, seemingly... Read more...